NEW YORK, June 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=85496&from=4CLASS PERIOD: February 3, 2022 to February 13, 20 ...

The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain.First, let’s highlight the major healthcare tailwinds starting with an aging population. The baby boomer generation (20% of the U.S. population) is transitioning into older age. This shift will create a surging demand for healthcare services and products such as insurance, pharmaceuticals, medical devices and hospitals.Indeed, esti ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Colorado on behalf of those who acquired Biogen, Inc (“Biogen” or the “Company”) (NASDAQ: BIIB) securities during the period of February 3, 2022 through February 13, 2024, inclusive (“the Class Period”). Investors have until July 22, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here t ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and F ...

会议主要讨论的核心内容 - Biogen公司在过去几年经历了重大转型 [4][5][6][7] - 公司现已进入稳定期并正在向增长转型 [5][6][7] - 公司正在优化资本配置以实现长期增长 [6][7] - 公司正在推出新产品并拓展管线 [7] LEQEMBI上市情况 - LEQEMBI上市10个月来经历了两个阶段 [11][12][13][14][15][16][17] - 3月份开始出现加速增长 [16][17][18][19][20] - 主要原因包括更多医生开始开具处方、医疗机构扩大患者数量 [16][17][18][19][20] - 公司正在扩大销售团队以支持进一步增长 [37][38][39][40] - 公司关注医生开具处方数量和医疗机构订单数量等指标 [25][26][27][28][29][30][31][32][33][34][35] - 预计竞争对手进入市场将有利于整体市场发展 [21][22][23] SKYCLARYS上市情况 - SKYCLARYS上市表现良好 [54][55][56][57][58][59] - 公司正在采取多种策略寻找更多患者 [56][57][58][59] - 预计儿童适应症获批将带来约500名新患者 [67][68] - 欧洲市场也有较大发展空间 [69][70][71] ZURZUVAE上市情况 - 与Sage公司合作共同推广 [73][74][75][76][77][78][79][80] - 出现意外情况,产品主要由妇产科医生而非精神科医生开具 [74][75][76][77] - 公司正在加强对医生的教育培训 [79][80] 公司整体情况 - 公司正在优化资本配置以提升利润率 [83][84][85][86][87][88] - 公司仍有业务拓展需求,未来将继续进行适当的并购 [85][86][87]

文章核心观点 - 公司正在经历从衰退到增长的转型,通过重新调整组织架构、优化资本配置等措施来提升财务纪律和长期收益 [3][4][5][6] - 公司主要产品LEQEMBI的上市推广正在加速,通过扩大销售团队、开展DTC营销等措施来推动患者数量增长 [26][27][34][35][36][37] - 公司新药SKYCLARYS在罕见病领域表现良好,正在积极拓展覆盖面,并期待通过扩大适应症来带来进一步增长 [48][49][50][60] - 公司与Sage合作的新药ZURZUVAE在产科医生群体中表现超预期,未来有望进一步提升市场份额 [66][67][68][69][70][71][72] - 公司正在通过优化资本配置、提升运营效率等措施来改善利润率,并保持积极的并购态度以推动长期增长 [74][75][76][77][78][79] 根据目录分组总结 LEQEMBI上市推广 - 公司正在通过扩大销售团队、开展DTC营销等措施来推动LEQEMBI的患者数量增长 [26][27][34][35][36][37] - 公司正在积极推进LEQEMBI的剂型扩展,包括静脉维持剂型和皮下注射剂型,以为患者提供更多选择 [39][40][41][42][43] - 公司对LEQEMBI在Medicare Part D改革下的定价和覆盖情况保持谨慎态度,将密切关注相关政策变化 [44][45][46][47] SKYCLARYS在罕见病领域的表现 - 公司在罕见病领域积累了丰富经验,SKYCLARYS在弗里德里希共济失调治疗领域表现良好 [48][49][50] - 公司正在积极拓展SKYCLARYS的覆盖面,包括通过AI模型发现更多潜在患者 [51][52][53] - 公司期待通过扩大适应症至儿童群体来带来进一步增长机会 [60] ZURZUVAE在产科领域的表现 - 公司与Sage合作推广ZURZUVAE,在产科医生群体中表现超预期 [65][66][67][68] - 公司正在积极应对产科医生在使用专科药房、事先授权等方面的教育需求 [71][72] - 公司对ZURZUVAE未来的增长前景保持乐观 [69][70] 公司整体经营情况 - 公司正在通过优化资本配置、提升运营效率等措施来改善利润率 [74][75][76] - 公司保持积极的并购态度,将继续寻求外部机会以推动长期增长 [77][78][79]

文章核心观点 - 多发性硬化症(MS)患者人数在过去20年中翻了一番,从2000年的40万人增加到2017年的90万人[1] - 现有的疾病修饰治疗(DMT)对大多数患者的症状和疾病进展控制效果不佳,尤其是对于非活动性继发性进行性MS(na-SPMS)患者[1] - 全球MS药物市场规模预计将从2024年的211.6亿美元增长到2032年的389.4亿美元,年复合增长率为7.9%[2] 根据目录分类总结 行业概况 - 全球MS患者人数从2013年的230万人增加到2020年的280万人,导致对有效诊断和治疗的需求不断增加[2] - 政府正在积极支持MS治疗,推动行业发展[2] 公司动态 - 泰泽纳生命科学公司(TLSA)向FDA申请获得快速通道认定,用于开发用于治疗na-SPMS的鼻内给药单克隆抗体药物foralumab[3][4] - 辉瑞公司(LLY)的tirzepatide在2期临床试验中显示可显著改善代谢相关性脂肪肝炎(MASH)患者的肝脏病理指标[5][6] - 罗氏公司(RHHBY)的Evrysdi®(risdiplam)在5年随访中持续显示对1型脊髓性肌萎缩症(SMA)儿童的疗效和安全性[7][8] - 辉瑞公司(BIIB)的QALSODY®(tofersen)获得欧盟上市许可,成为首个获批针对SOD1基因突变引起的ALS的治疗药物[8][9] - 泰格公司(TGTX)公布了BRIUMVI®(ublituximab-xiiy)在复发型MS患者中的2期临床试验设计[11][12]

NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation. Why is Biogen being Sued? On May 22, 2024, Biogen was sued for violations of the federal securities laws. The complaint alleges that between February 3, 2022 and F ...

LOS ANGELES, June 10, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB).Class Period: February 3, 2022 – February 13, 2024Lead Plaintiff Deadline: July 22, 2024If you are a shareholder who suffered a loss, click here to participate.The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to i ...

Biogen (BIIB) and Japanese partner Eisai announced that the FDA has accepted Eisai’s supplemental biologics license application (sBLA) seeking approval for a maintenance intravenous (“IV”) dosing version of Leqembi for the treatment of early Alzheimer’s disease. The FDA is expected to give its decision on the sBLA on Jan 25, 2025.Leqembi was approved as an injection for intravenous use by the FDA for early Alzheimer’s disease in the United States in July 2023. Leqembi is also approved in China and Japan. Re ...